Medtronic has reported positive results from a study of its MiniMed 780G automated insulin delivery system in addressing burdensome challenges of diabetes.
The data indicates the system’s ability in managing hyperglycemia and reducing night-time disruptions for people with type 1 diabetes.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Designed for use by type 1 diabetes patients, the MiniMed 780G system is intended for the continuous delivery of basal insulin at selectable rates and amounts.
The study focused on the dawn phenomenon, a common cause of elevated morning glucose levels.
A retrospective analysis of data from 6,026 patients showed that those switching from the MiniMed 770G to the MiniMed 780G experienced a significant reduction in morning glucose peaks.
The incidence of the dawn phenomenon dropped from 12.2% to 4.5%, and time in range improved from 87.7% to 91.4% between midnight and 6am.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurther data from 8,019 patients, including children under seven, indicated that the MiniMed 780G system’s automatic insulin adjustments every five minutes led to fewer overnight interruptions and better glucose control.
Night-time alerts decreased by 45%, and users gained an additional 30鈥�36 minutes of uninterrupted sleep.
Currently, the MiniMed 780G system is available for individuals aged seven and older in more than 100 countries.
Medtronic is also developing the next version of the MiniMed 780G system to further ease diabetes management.
Medtronic Diabetes chief medical officer Robert Vigersky said: 鈥淔or those living with type 1 diabetes, dawn phenomenon can be a stressful occurrence that feels out of one’s control.
鈥淭he introduction of the MiniMed 780G system has made it easier to maintain target glucose range with less effort to protect against hyperglycemia. It has been an absolute gift for my patients who have struggled with stubborn highs throughout their diabetes journey.鈥�
In 2022, Health Canada issued a licence to Medtronic鈥檚 MiniMed 780G insulin pump system.
